Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.

Inclusion Criteria:

• Kidney transplant recipients with confirmed transplant glomerulopathy on kidney biopsy.
• Failed standard therapy (>25% reduction in proteinuria) including maximum use of an ACE inhibitor, ARB, or aldosterone blocker with a goal blood pressure less than 130/80 and optimization of their immunosuppression

Exclusion Criteria:

• Diabetes